Sign in

    Herriot Tabuteau

    Founder, Chief Executive Officer, President, and Chairman of the Board at Axsome Therapeutics Inc
    Board
    Since January 2012
    Age
    55 years
    Education
    Earned an M.D. from Yale University School of Medicine and a Bachelor's degree in molecular biology and biochemistry from Wesleyan University.
    Tenure
    Joined Axsome Therapeutics at its founding in January 2012, serving as Founder, Chief Executive Officer, President, and Chairman of the Board.

    Also at Axsome Therapeutics Inc

    AM
    Ari Maizel
    Chief Commercial Officer
    HM
    Hunter Murdock
    General Counsel
    LE
    Lori Englebert
    Executive Vice President, Product Strategy

    About

    Herriot Tabuteau is the Founder, Chief Executive Officer, President, and Chairman of the Board at Axsome Therapeutics, having established and led the company since January 2012.

    He earned his M.D. from Yale University School of Medicine and a Bachelor's degree in molecular biology and biochemistry from Wesleyan University, laying a strong academic foundation for his career in healthcare and biotechnology.

    Prior to founding Axsome, he held several influential roles in healthcare investment and research, contributing as a Senior Analyst, Partner, and investment banking professional at various firms. His early career helped shape the strategic vision that he brings to his leadership at Axsome Therapeutics.

    $AXSM Performance Under Herriot Tabuteau

    Past Roles

    OrganizationRoleDate RangeDetails
    Healthco/S.A.C. Capital (now known as HealthCor) Senior Analyst and Partner N/A Responsible for the biotechnology, genomics, and instrumentation portfolios
    Kingdon Capital Healthcare Analyst N/A N/A
    Banc of America Securities Senior Research Analyst N/A Covered the hospital supplies sector
    Goldman Sachs Healthcare Investment Banking Group Member N/A N/A

    External Roles

    OrganizationRoleDate RangeDetails
    Antecip Capital LLC Founder and Managing Member 2003 - Present One of Axsome's principal stockholders
    Antecip Bioventures II LLC Managing Member N/A Involved in exclusive license agreements with Axsome

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Salary$750,000 Annual9.5% increase from 2022 base salary ($685,000)
    All Other Compensation$82,961 AnnualIncludes FICA tax payments and 401(k) match contributions

    Performance Compensation

    Data from  FY 2023

    Stock Awards

    Restricted Stock Units (RSUs)

    • Grant Date: March 2, 2023.
    • Number of Shares Granted: 62,400 RSUs.
    • Grant Date Fair Value: $2,834,520.
    • Vesting Schedule: Four equal annual installments over four years, fully vested on March 2, 2027 (with provisions for Change in Control, separation, or after seven years).
    • Performance Metric: Based entirely on total shareholder return.

    Stock Options

    • Grant Date: March 2, 2023.
    • Number of Shares Granted: 110,032 stock options.
    • Exercise Price: $65.32 per share.
    • Grant Date Fair Value: $5,666,648.
    • Vesting Schedule: 16 equal quarterly installments over four years, fully vested on March 2, 2027 with a ten-year term.
    • Performance Metric: Value is driven by stock price appreciation.

    Non-Equity Incentive Plan Compensation

    • Target Bonus: $450,000 (60% of base salary).
    • Maximum Bonus: $900,000 (200% of target bonus).
    • Actual Payout: $562,500 (125% of target bonus).
    • Performance Metrics & Weights:
      • Advance Our Pipeline: 30%.
      • Drive Business Performance: 30%.
      • Drive Business Expansion: 20%.
      • Increase Awareness of Our Science, Business, and Products: 20%.
    • Evaluation Period & Conditions: Based on meeting operational performance goals including launching new target indications, completing development milestones, growing product sales, improving cash runway, securing licensing agreements, and expanding the field sales team.